Severe, even life-threatening peanut allergies afflict 3 million people in the United States alone. The only protection now available is to avoid peanuts and their derivatives. While it’s easy to eschew peanut butter sandwiches, who’s to know if the chips at the office party were fried in peanut oil? Houston-based Tanox has begun human testing of a once-a-month injection to protect the peanut-averse from accidental exposure. The drug, Hu-901, is an antibody that blocks the immune reaction responsible for swelling and itching. People taking it probably won’t be able to eat nuts daily, but they should have more time to get help if they do eat those chips.
If Hu-901 is effective in preventing peanut allergies, Tanox may investigate its use against other food allergies. The company hopes a similar antibody to treat seasonal allergies and asthma will get regulatory approval by mid-2001.
Investing in people is key to successful transformation
People-related factors like talent attraction and retention and clear top-down communication will determine whether your transformation progresses or stalls.
Work reinvented: Tech will drive the office evolution
As organizations navigate a new world of hybrid work, tech innovation will be crucial for employee connection and collaboration.
The way forward: Merging IT and operations
Digital transformation in any industry begins with bridging the gap between two traditionally separate teams.
Be a good example
"It was in the newspaper, but the towers fell the next day, and what I’d done was quickly lost."
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.